EBS:NYSE
Emergent Biosolutions Inc
6,91 USD
arrow_downward
−1,00%(−0,070) 1D
6,86 USD
arrow_downward
−0,72% (−0,050)bedtimeNakon radnog vremena
Zatvoreno: 13. lis, 16:00:02 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za EBS...
Otvori
6,95 USD
Najviša
7,07 USD
Najniža
6,85 USD
Trž. kap.
354,30 mil.
Prosj. kol.
1,15 mil.
Količina
0,00
52-tjed. najviša
14,06 USD
52-tjed. najniža
4,36 USD
EPS
−3,51 USD
Beta
2,28
Dionice u optjecaju
51,27 mil.
Broj djelatnika
900
Otvori
6,95 USD
Najviša
7,07 USD
Najniža
6,85 USD
Trž. kap.
354,30 mil.
Prosj. kol.
1,15 mil.
Količina
0,00
52-tjed. najviša
14,06 USD
52-tjed. najniža
4,36 USD
EPS
−3,51 USD
Beta
2,28
Dionice u optjecaju
51,27 mil.
Broj djelatnika
900
Vijesti
Iz web-izvora i od partnera za vijesti
Naslovi.net
·
prije 21 sat
Wall Street: Micron gubitnik dana, samo Dow Jones u plusu
Seeking Alpha
·
prije 39 minuta
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss - Slideshow (NASDAQ:BMEA) 2026-10-14
Yahoo Finance
·
prije 2 sata
Dow, S&P 500, Nasdaq Futures Mixed Amid Rising Oil Prices Ahead Of CPI Data: BAC, RIVN, SLS, GME Stocks In Focus
The Motley Fool
·
prije 2 minute
The S&P 500 Just Hit a Record High. Here's Why History Says It's Still a Smart Time to Invest.
Profil
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
Emergent Biosolutions Inc – informacije
Glavni izvršni direktorRobert G. Kramer Sr. | Joseph C. Papa
Zaposlenici900
Osnovano5. ruj 1998.
SjedišteRockville, Maryland, Sjedinjene Američke Države
Sektor-
Web-lokacijaemergentbiosolutions.com